Synta Pharmaceuticals Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS Follows Positive Interim Analysis of Phase 2 Results - - First of Three Randomized Studies Sponsored by Cardiff University and Supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to Include ... (more)
http://ift.tt/UpWfoo
http://ift.tt/UpWfoo
No comments:
Post a Comment